Free tool
Cell therapy stocks
We cover 39 companies grouped under the Cell therapy theme. The median market value in the group is $488.86M. Across the group, the median move over the past trading day is +2.36%. 66% of the 38 with a 200-day average trade above it. Price change over the past year runs from −38.9% to +236.6% across the middle 80 percent of the group, with a median of +19.1%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
39 of 86 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporation | $21.30 | +10.53% | −0.98% | −38.44% |
| IOVA | Iovance Biotherapeutics, Inc. | $8.44 | +72.24% | +234.92% | +233.60% |
| MSB.AX | Mesoblast Limited | 2.40 AUD | +16.26% | −13.54% | −3.82% |
| MESO | Mesoblast Limited | $17.19 | +18.06% | −5.34% | +9.42% |
| VCEL | Vericel Corporation | $43.22 | −4.63% | +21.37% | +20.76% |
| BLFS | BioLife Solutions, Inc. | $37.22 | +24.94% | +55.80% | +45.11% |
| VOR | Vor Biopharma Inc. | $24.01 | +23.51% | +106.27% | −41.72% |
| SANA | Sana Biotechnology, Inc. | $4.10 | +25.00% | −2.15% | +22.39% |
| IMMX | Immix Biopharma, Inc. | $14.47 | +66.51% | +166.48% | +589.05% |
| SYNC.L | Syncona Limited | 111.40 GBP | +5.69% | +16.65% | +15.68% |
| CYRX | Cryoport, Inc. | $16.72 | +10.36% | +74.90% | +89.78% |
| ALLO | Allogene Therapeutics, Inc. | $2.17 | +24.00% | +60.74% | +87.07% |
| PROK | ProKidney Corp. | $1.73 | +12.34% | −22.42% | −26.38% |
| AUTL | Autolus Therapeutics plc | $2.44 | +67.12% | +30.48% | +52.50% |
| ARTV | Artiva Biotherapeutics, Inc. | $11.77 | +14.05% | +178.25% | +317.38% |
| KYTX | Kyverna Therapeutics, Inc. | $8.84 | +11.62% | +0.80% | +132.02% |
| CABA | Cabaletta Bio, Inc. | $3.22 | +18.38% | +45.70% | +102.52% |
| 0JDK.L | Iovance Biotherapeutics, Inc. | $8.36 | +1.91% | +222.92% | +248.46% |
| 4592.T | SanBio Company Limited | 1,024.00 JPY | +10.58% | −37.45% | −55.90% |
| CAPR | Capricor Therapeutics, Inc. | $8.29 | +18.43% | −70.72% | +25.61% |
| 005690.KS | Pharmicell Co., Ltd. | 10,830.00 KRW | +10.85% | −24.90% | +1.56% |
| 0HX7.L | Adicet Bio, Inc. | $9.03 | +0.56% | +5.00% | −24.75% |
| IPSC | Century Therapeutics, Inc. | $2.17 | +3.83% | +118.09% | +324.66% |
| LYEL | Lyell Immunopharma, Inc. | $15.49 | +19.52% | −46.55% | +41.20% |
| ALCLS.PA | Cellectis S.A. | 2.76 EUR | +9.63% | −34.61% | +19.05% |
| CLLS | Cellectis S.A. | $3.42 | +18.34% | −28.75% | +27.14% |
| 219A.T | HEARTSEED INC | 2,365.00 JPY | +36.94% | +31.02% | −32.33% |
| FATE | Fate Therapeutics, Inc. Common Stock | $2.55 | +4.94% | +157.58% | +133.94% |
| RNAC | Cartesian Therapeutics, Inc. | $10.38 | +33.25% | +53.55% | −7.73% |
| 4894.T | Cuorips Inc. | 5,670.00 JPY | +37.29% | −8.84% | −19.00% |
| LCTX | Lineage Cell Therapeutics, Inc. | $1.13 | +9.71% | −31.10% | −3.42% |
| 4593.T | Healios K.K. | 283.00 JPY | +25.22% | +0.71% | −40.92% |
| 7774.T | Japan Tissue Engineering Co., Ltd. | 875.00 JPY | +41.82% | +49.57% | +79.30% |
| NKTX | Nkarta, Inc. | $2.71 | +19.91% | +44.92% | +23.18% |
| 504A.T | Innovacell Inc. | 555.00 JPY | +17.34% | −47.14% | −47.14% |
| OCC.AX | Orthocell Limited | 0.78 AUD | +9.86% | −30.36% | −35.00% |
| MXCT | MaxCyte, Inc. | $1.35 | +32.35% | −12.90% | −2.88% |
| 0HIY.L | Atara Biotherapeutics, Inc. | $9.92 | +1.60% | −44.67% | −20.36% |
| DTSQU | DT Cloud Star Acquisition Corporation | $11.49 | 0.00% | +4.95% | +9.95% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.